NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
Clinical Trials
10 trialsNCT01543763 2025-03-21
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT01468922 2022-07-01
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03139331 2021-01-05
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
University of California, San Francisco
Phase 1 Completed
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT01438554 2018-08-29
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01985295 2015-10-09
PASART-1
The Netherlands Cancer Institute
Phase 1 Completed